Published in Therapie on April 13, 1988
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol (2000) 5.20
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer (2006) 2.75
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol (2002) 1.44
[Pneumopathy caused by methotrexate]. Rev Mal Respir (1990) 1.19
Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol (2007) 1.18
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer (2011) 1.14
Impact of an intensive communication strategy on end-of-life practices in the intensive care unit. Intensive Care Med (2011) 1.11
Acute myocardial infarction related to myocardial bridging. Eur Heart J (1995) 1.10
Suffering among carers working in critical care can be reduced by an intensive communication strategy on end-of-life practices. Intensive Care Med (2011) 0.99
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol (2012) 0.99
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer (2007) 0.98
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma. Br J Cancer (2009) 0.94
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol (2012) 0.89
Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women. Eur J Nucl Med (1996) 0.88
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer (2010) 0.88
Types of interaction of amphiphilic drugs with phospholipid vesicles. J Pharmacol Exp Ther (1988) 0.86
Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res (1999) 0.86
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. Eur Respir J (2011) 0.85
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Ann Oncol (2010) 0.85
Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy. J Oncol (2013) 0.84
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol (2002) 0.83
Impairment of diastolic function during short-term anthracycline chemotherapy. Br Heart J (1995) 0.82
[Type E botulism. Two recent cases (author's transl)]. Nouv Presse Med (1982) 0.82
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. Eur J Cancer (2003) 0.82
A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. Gynecol Oncol (1999) 0.82
Can severe acute pain escape visual analog scale screening in the ED? Am J Emerg Med (2004) 0.81
Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells. Br J Cancer (1987) 0.81
Risk factors for septic shock in the early management of bacteremia. Am J Med (1992) 0.81
Age and prognosis of non-small cell lung cancer. Usefulness of a relative survival model. Eur J Cancer (1993) 0.79
Plasma lipid peroxidation in critically ill patients: importance of mechanical ventilation. Free Radic Biol Med (1994) 0.79
[Management of metastatic HER2-positive breast cancer: present and future]. Bull Cancer (2010) 0.78
[Hemorrhagic fever with renal syndrome. A case with diarrhea and rhabdomyolysis]. Presse Med (1985) 0.78
p53 gene alterations are associated with a decreased responsiveness to neoadjuvant chemotherapy in human breast cancer. Int J Oncol (1997) 0.78
Nilutamide pneumonitis: a report on eight patients. Thorax (1992) 0.78
[Ambulatory Essure implant placement sterilization procedure for women: prospective study comparing general anesthesia versus hypnosis combined with sedation]. Ann Fr Anesth Reanim (2010) 0.78
[Acute carbon monoxide poisoning in the emergency service. The importance of early signs. 90 cases]. Ann Med Interne (Paris) (1983) 0.78
Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol (1998) 0.77
MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res (2000) 0.77
[Spontaneous intracerebral hemorrhages in young patients. Study of 33 cases]. Rev Neurol (Paris) (1991) 0.77
[Acute severe pain in emergencies. The key for efficient analgesia]. Ann Fr Anesth Reanim (2001) 0.77
[Respiratory manifestations of hemorrhagic rectocolitis]. Rev Mal Respir (1991) 0.76
[Medical demographics and dermatology under fire]. Ann Dermatol Venereol (2013) 0.75
Co-morbidities and prognosis of bacteremia. Intensive Care Med (1994) 0.75
Immunophenotype in erythroleukemia secondary to myelodysplastic syndrome. Blood (1992) 0.75
[Septicaemias observed in intensive care. Causes (author's transl)]. Anesth Analg (Paris) (1979) 0.75
[Acute renal failure caused by rifampicin. A case]. Therapie (1982) 0.75
Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study. Eur J Cancer Care (Engl) (2013) 0.75
[Premature loss and persistence of milk teeth beyond normal age]. Cah Odontostomatol Touraine (1979) 0.75
Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study. J Exp Clin Cancer Res (2001) 0.75
[Nitrosourea-induced lung diseases]. Rev Mal Respir (1992) 0.75
[Oral galvanism: study with emission spectrography of a salivary electrolyte]. Inf Dent (1979) 0.75
[What should our attitude be in a case of dental agenesis?]. Cah Odontostomatol Touraine (1980) 0.75
[Role of alcoholism in an emergency unit]. Presse Med (1983) 0.75
[Impact of the Activity-Based Financing (11th Version) on glaucoma surgery payment in hospital resources]. J Fr Ophtalmol (2009) 0.75
[Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time]. Bull Cancer (1997) 0.75
[Modification of septicaemias in an intensive care unit following the suppression of prophylactic antibiotics (author's transl)]. Nouv Presse Med (1979) 0.75
[Renal tubular necrosis and cytolytic hepatitis following repeated anaesthetic inhalation of methoxyflurane]. Eur J Toxicol (1973) 0.75
[Value of sphenoidal electrodes in the EEG diagnosis of herpes encephalitis]. Neurophysiol Clin (1990) 0.75
[Clinical, anesthesiological and evolutive problems caused by pseudo-surgical botulism of type E]. Anesth Analg (Paris) (1974) 0.75
Pharmacokinetics of amiodarone in the isolated rat lung. J Pharmacol Exp Ther (1990) 0.75
[The palliative care in geriatrics: a retrospective study of 40 cases]. Rev Med Interne (2005) 0.75
[Hypoglycemia during a treatment with interferon-alpha]. Presse Med (1997) 0.75
[Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer]. Bull Cancer (1999) 0.75
Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance. Anticancer Res (1990) 0.75
[Comparison of relative survival vs. classical survival. Apropos of primary bronchial cancer]. Bull Cancer (1994) 0.75
[Drug-induced respiratory complications. Study of 27 cases]. Therapie (1989) 0.75
Bone metastases from a melanoma of the anal verge. Rev Rhum Engl Ed (1998) 0.75
Pharmacokinetics and metabolism of nilutamide in the isolated rat lung. J Pharmacol Exp Ther (1991) 0.75
[Reflections on the management of suspected recent pulmonary embolism]. Agressologie (1991) 0.75
[Pulmonary edema with low pulmonary capillary pressure in cardiogenic shock treated successfully by volume replacement: 2 cases]. Ann Med Interne (Paris) (1986) 0.75
[Macromolecules, the reticuloendothelial system and immunologic problems]. Anesth Analg (Paris) (1977) 0.75
[Multiple cerebral embolism in acute alcoholic intoxication. A pathological case]. Rev Neurol (Paris) (1992) 0.75
[Peroperative acute pulmonary edema in a patient with a healthy heart. Apropos of a case]. Anesth Analg (Paris) (1977) 0.75
[End-of-life and euthanasia, an intensive care team's experience]. Presse Med (2002) 0.75
Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching. Eur J Cancer (2012) 0.75
[Surgical treatment of medical pyomyositis]. Presse Med (1986) 0.75
[Electrochemical behavior of dental amalgams in the environment of reconstituted saliva]. Inf Dent (1979) 0.75
[Viper bites. Myth or reality]. Presse Med (1983) 0.75
[Pulmonary edema due to peroperative overload or anesthetic awakening]. Ann Anesthesiol Fr (1977) 0.75
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]. Ann Biol Clin (Paris) (2002) 0.75
[Dermatosis caused by trichloroethylene in a drug addict]. Presse Med (1987) 0.75
[Digestive disorders of marathon runners]. Presse Med (1987) 0.75
[Neurological toxicity of colistine methane sulfonate, about a case (author's transl)]. Toxicol Eur Res (1979) 0.75
Multifocal malignant fibrous histiocytoma of the spine. Rev Rhum Engl Ed (1997) 0.75
Changing practice in systemic breast cancer adjuvant treatment in a well-defined French population. Bull Cancer (1999) 0.75
[Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma]. Rev Pneumol Clin (2000) 0.75
[Is apomorphine still usable?]. Presse Med (1986) 0.75
[Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV]. Bull Cancer (1996) 0.75
[Legionella gormanii Legionnaires' disease?]. Presse Med (1984) 0.75